Roivant Sciences Ltd faces a challenging day as its stock price declines after recent clinical setbacks.
Roivant Sciences Ltd (NASDAQ:ROIV) is experiencing a significant downturn, with shares sliding 2.44% today. This decline follows mixed clinical trial results that have raised concerns about the company's future prospects.
Investor takeaway: Investors should remain cautious as Roivant's recent clinical results may not translate into commercial success, highlighting the risks inherent in biopharmaceutical investments.
Advertisement
Roivant Sciences Ltd
ROIV.US
ROIV.US
Roivant Sciences Ltd
WealthAwesomeMarket cap
$25.86B
52W high
$42.50
52W low
$15.11
1W change
-5.16%
Beta
1.12
Analyst Price Targets
Based on 10 analysts covering ROIV · as of Sep 25, 2026
Wall Street analysts forecast ROIV stock price to rise 30.0% over the next 12 months.
Consensus
Strong Buy4.50 / 5.00
Avg. Target
C$48.08
+30.0% Upside
Previously C$47.79 on Sep 21, 2026
Current Price
C$36.98
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ROIV's historical volatility
30-Day Vol
61.8%
Annualized
90-Day Vol
47.7%
Annualized
Trend (90d)
+21.6%
Annualized drift
90d Mean
C$39.94
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$37.94 | C$30.66 – C$46.96 |
| 60 trading days | C$38.93 | C$28.79 – C$52.63 |
| 90 trading days | C$39.94 | C$27.61 – C$57.78 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Roivant's stock down 2.44% today
The decline reflects investor skepticism following clinical trial results that failed to meet expectations.
Bull case
Roivant's pipeline includes promising candidates like mosliciguat, which recently showed positive Phase 2 results. This suggests there could be potential for future growth.
Bear case
Despite some positive results, the mixed outcomes from recent trials and the competitive landscape for treatments could hinder Roivant's ability to capitalize on its pipeline.
Advertisement
Recent Clinical Developments
Roivant's recent announcement about the Phase 2 results for mosliciguat, an experimental treatment for pulmonary hypertension, initially sparked optimism. However, mixed results from the proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus have dampened investor sentiment. The study did not achieve statistical significance on its primary endpoint, raising doubts about the viability of this treatment.
Market Reaction and Future Outlook
The market's reaction to Roivant's recent clinical results indicates a cautious approach from investors. With the stock sliding 2.44%, there is growing concern that the company's ambitious pipeline may not deliver the anticipated results. As Roivant transitions from clinical trials to commercialization, it faces significant hurdles that could impact its long-term growth trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
